Skip to content
Disclosery

Symmetry Investments LP: XLE position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Symmetry Investments LP on XLE, newest first. How the timeline and the estimate are built.

Symmetry Investments LP held 0 XLE shares at 2026-06-30 per its 13F-HR filed 2026-08-14.

the latest 13F is the newest step

  1. period ended2026-06-30
    13F 0 shares
    Change vs previous 13F -98,600 shares

    13F-HR 0001691919-26-000009 filed by Symmetry Investments LP
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

    Exited: the 13F for this period no longer lists the position.

  2. period ended2026-03-31
    13F 98,600 shares
    Change vs previous 13F +98,600 shares

    1.47% of the 13F portfolio, value $6,040,236.

    13F-HR 0001691919-26-000004 filed by Symmetry Investments LP
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2025-03-31
    13F 0 shares
    Change vs previous 13F -14,600 shares

    13F-HR 0001691919-25-000030 filed by Symmetry Investments LP
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

    Exited: the 13F for this period no longer lists the position.

  4. period ended2024-12-31
    13F 14,600 shares
    Change vs previous 13F -15,200 shares

    0.07% of the 13F portfolio, value $1,250,636.

    13F-HR 0001691919-25-000005 filed by Symmetry Investments LP
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2024-09-30
    13F/A 29,800 shares
    Change vs previous 13F not available

    0.56% of the 13F portfolio, value $2,616,440.

    13F-HR/A 0001691919-25-000028 filed by Symmetry Investments LP
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).